Huimin Jin

Huimin Jin

Auto-generated profile, based on publicly available information

Huimin Jin

Department of Histology and Embryology, Hengyang Medical School, University of South China, Hengyang, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2024 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZYZhouchi Yao
Zhouchi Yao
YZYayun Zeng
Yayun Zeng
CLCheng Liu
Cheng Liu
HJHuimin Jin
Huimin Jin
HWHong Wang
Hong Wang
DWDaichao Wu
Daichao Wu
Vigorous CD8+ T cells play a crucial role in recognizing tumor cells and combating solid tumors. How T cells efficiently recognize and target tumor antigens, and how they maintain the activity in the “rejection” of solid tumor microenvironment, are major concerns. Recent advances in understanding of the immunological trajectory and lifespan of CD8+ T cells have provided guidance for the design of more optimal anti-tumor immunotherapy regimens. Here, we review the newly discovered methods to enhance the function of CD8+ T cells against solid tumors, focusing on optimizing T cell receptor (TCR) expression, improving antigen recognition by engineered T cells, enhancing signal transduction of the TCR-CD3 complex, inducing the homing of polyclonal functional T cells to tumors, reversing T cell exhaustion under chronic antigen stimulation, and reprogramming the energy and metabolic pathways of T cells. We also discuss how to participate in the epigenetic changes of CD8+ T cells to regulate two key indicators of anti-tumor responses, namely effectiveness and persistence.

1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
HJHuimin Jin
Huimin Jin
YFYuqian Feng
Yuqian Feng
YXYuying Xiang
Yuying Xiang
YZYiting Zhang
Yiting Zhang
WDWurong Du
Wurong Du
DHDawei Huang
Dawei Huang
Background. Acupuncture‐moxibustion therapy (AMT), as an integral part of complementary and alternative medicine, has been used for centuries in treatment of numerous diseases. Nevertheless, there is no available supportive evidence on the efficacy and safety of acupuncture‐moxibustion therapy in patients with chemotherapy‐induced leukopenia (CIL). The purpose of this study is to evaluate the efficacy and safety of acupuncture‐moxibustion therapy in treating chemotherapy‐induced leukopenia. Methods. Relevant studies were searched in nine databases up to September 19, 2020. Two reviewers independently screened the studies for eligibility, extracted data, and assessed the methodological quality of selected studies. Meta‐analysis of the pooled mean difference (MD) and risk ratio (RR) with their respective 95% confidence intervals (CI) were calculated. Results. 17 studies (1206 patients) were included, and the overall quality of the included studies was moderate. In comparison with medical therapy, AMT has a better clinical efficacy for CIL (RR, 1.24; 95% CI, 1.17‐1.32; P < 0.00001) and presents advantages in increasing leukocyte count (MD, 1.10; 95% CI, 0.67–1.53; P < 0.00001). Also, the statistical results show that AMT performs better in improving the CIL patients’ Karnofsky performance score (MD, 5.92; 95% CI, 3.03–8.81; P < 0.00001). Conclusion. This systematic review and meta‐analysis provides updated evidence that AMT is a safe and effective alternative for the patients who suffered from CIL.